Drug Trial Radar · NCT06694701
Emapalumab Treatment For Anticipated Clinical Benefit In Sepsis Driven By The Interferon-Gamma Endotype (The EMBRACE Trial)
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
75
Actual
Start
Mar 14, 2025
Primary completion
Mar 13, 2026
Study completion Sep 14, 2026
Sponsor
- Lead sponsor
- Hellenic Institute for the Study of SepsisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
EMBRACE is a double-blind, randomized, placebo-controlled, phase IIa study that will be conducted in multiple Intensive Care Units (ICUs) and departments of Internal Medicine across Greece. It aims to investigate if treatment with emapalumab, a monoclonal antibody which blocks IFNγ, may improve the outcome of patients with sepsis driven by the IDS (endotype of IFNγ-driven sepsis) endotype. EMBRACE also aims to identify the best dosing regimen of emapalumab for the management of IDS.
Conditions
- Sepsis
Interventions
Emapalumab-IzsgDrug
The drug is administered at a dose of 6mg/kg of body weight on day 0 and repeated dosing of 3mg/kg of body weight is provisioned for days 3, 6, 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply.
Emapalumab-IzsgDrug
The drug is administered at a dose of 6mg/kg of body weight on day 0, 6mg/kg of body weight on day 3, 6mg/kg of body weight on day 6 and repeated dosing of 3mg/kg of body weight is provisioned for days 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply.
PlaceboDrug
250ml of 0.9% sodium chloride. The drug is administered on day 0 and repeated dosing is provisioned for days 3, 6, 9, 12, 15, 19, 23 and 27 provided that the stopping rule does not apply
Primary outcomes
What the sponsor says the trial is designed to measure.
- Decrease of SOFA score by the end-of-treatmentTime frame: From enrollment to the end of treatment of the study drug for each of the study participants, ranging from 2 to 29 days.
Locations
24 sites in 1 country. Site status is shown where the registry gives one.
Intensive Care Unit, Alexandroupolis University General Hospital
Alexandroupoli, Greece
3rd University Department of Internal Medicine, Sotiria Chest Diseases Athens General Hospital
Athens, Greece
4th Department of Internal Medicine, ATTIKON University General Hospital
Athens, Greece
Intensive Care Unit I, KAT Attica General Hospital
Athens, Greece
Intensive Care Unit of 1st University Department Respiratory Medicine, Sotiria Chest Diseases Athens General Hospital
Athens, Greece
Intensive Care Unit of Center for Respiratory Failure, Sotiria Chest Diseases Athens General Hospital
Athens, Greece
Intensive Care Unit, Asklipieio Voulas General Hospital
Athens, Greece
Intensive Care Unit, Ippokrateio Athens General Hospital
Athens, Greece
Intensive Care Unit, Korgialeneio-Benakeio HRC Athens General Hospital
Athens, Greece
Intensive Care Unit, Laiko Athens General Hospital
Athens, Greece
New Multivalent Intensive Care Unit, Sotiria Chest Diseases Athens General Hospital
Athens, Greece
Ηigh Dependency Unit of Department of Clinical Therapeutics, Alexandra Athens General Hospital
Athens, Greece
Intensive Care Unit, Patras University General Hospital
Pátrai, Greece
1st Intensive Care Unit, G. Papanikolaou Thessaloniki General Hospital
Thessaloniki, Greece
Department of Anesthesiology and Intensive Care, AHEPA Thessaloniki University General Hospital
Thessaloniki, Greece
Intensive Care Unit, 424 General Military Training Hospital
Thessaloniki, Greece
Intensive Care Unit, Aghios Dimitrios Thessaloniki General Hospital
Thessaloniki, Greece
Intensive Care Unit, G. Gennimatas Thessaloniki General Hospital
Thessaloniki, Greece
Intensive Care Unit, Ippokrateio Thessaloniki General Hospital
Thessaloniki, Greece
Intensive Care Unit, Papageorgiou Thessaloniki General Hospital
Thessaloniki, Greece
Intensive Care Unit, Theageneio Thessaloniki Cancer Hospital
Thessaloniki, Greece
1st Department of Internal Medicine, Thriasio Elefsis General Hospital
Elefsina, Attica, Greece
Clinic of Intensive Care and Pulmonary Diseases, Aghioi Anargyroi Kifissia General Oncologic Hospital
Kifissia, Attica, Greece
Intensive Care Unit, University General Hospital of Heraklion
Heraklion, Crete, Greece
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.